Thesis (Ph. D.)--University of Oregon, 2008. / Typescript. Includes vita and abstract. Includes bibliographical references (leaves 93-106). Also available online in Scholars' Bank; and in ProQuest, free to University of Oregon users.

No description available.

Myotonic dystrophy is the commonest form of adult muscular dystrophy. Myotonic dystrophy 1 and 2 (DM 1 and DM 2) are autosomal dominant inherited disorders with unusual multisystem clinical features characterized by myotonia, progressive muscle weakness and wasting, cataracts, hypogonadism, frontal balding, cardiac conduction defects and diabetes. Severity varies from asymptomatic to severely affected phenotypes. DM1 presents with predominantly distal weakness whereas DM2 have predominantly proximal weakness.98% of patients identified worldwide present with DM1. DM 1 is caused by the expansion of an unstable CTG trinucleotide repeat in the 3' untranslated region of the myotonic dystrophy protein kinase gene on chromosome 19ql3.3. DM 2 is linked to the long arm of chromosome 3q21. It is caused by a tranucleotide, CCTG expansion in intron 1 of the zinc finger protein 9(ZNF9) gene that interferes with processing of a variety of RNAs. All DM mutations can be detected using a combination of the Southern Blot and Polymerase Chain reaction (PCR) techniques. Aim: This study aims to characterize the clinical spectrum and molecular features of myotonic dystrophy patients in KwaZulu - Natal between 1989 and 2005. Methodology: Patients included in this study were obtained from the database of patients diagnosed with Myotonic Dystrophy at the Department of Neurology in KwaZulu-Natal from 1989 to 2005. Patients were subjected to clinical, radiological and neurophysiological assessment. Molecular testing was performed using PCR and Southern blot. Results: Thirty-seven patients with Myotonic Dystrophy were identified. Twenty patients consented and were included into the study. Eighty-five percent of patients were of Indian descent and the remaining fifteen percent were White. No African patients were identified. Sixty-five percent were male and thirty-five percent female. Myotonia was clinically present in all patients. Ninety-five percent of patients presented with predominantly distal weakness of which 40% demonstrated mild weakness, 35% moderate weakness and 25 % severe weakness. No patients were identified with predominantly proximal wasting or weakness. Southern blotting demonstrated expanded CTG repeats (DM1) in all 20 samples analysed. The PCR analysis was unable to demonstrate expanded alleles. Conclusion: This study identified patients presenting with Myotonic dystrophy to the Department of Neurology in KwaZulu-Natal and demonstrated that Myotonic Dystrophy Type 1 remains the commonest clinical and molecular presentation. In addition it substantiated previous research findings wherein no South African of African descent was found to be affected by the disease. There have been no reported cases of Myotonic Dystrophy in African Black patients presenting to the Department of Neurology in Durban, no African Black patients have been diagnosed with Myotonic Dystrophy over the past 20 years. However ,the predominance of Indians in this study is more likely a reflection of referral bias than differing incidence amongst sections of the population. PCR analysis cannot detect trinucleotide repeat expansions beyond 200 repeats and as a result Southern Blotting remains the gold standard in obtaining a molecular diagnosis. A clinical diagnosis is sufficient and molecular confirmation is not an absolute requirement. / Thesis (M.Med)-University of KwaZulu-Natal, Durban, 2006.

No description available.

Les syndromes myotoniques congénitaux atypiques dus à des mutations du canal sodé voltage-dépendant Nav1.4 se distinguent des myotonies congénitales classiques (canal chlore ClC-1) par la présence de traits atypiques incluant des myotonies douloureuses aggravées au froid et à l’ingestion de potassium. La caractérisation clinique et moléculaire de plusieurs familles atteintes de ces conditions rares dans la région du Saguenay-Lac-St-Jean nous a permis de découvrir une nouvelle mutation SCN4A à effet fondateur causant un phénotype de myotonies douloureuses aggravées au froid, parfois accompagné de phénomènes dystrophiques ou paralytiques. L’ampleur de notre cohorte nous permet de commenter sur l’hétérogénité phénotypique observée, sur les traits caractéristiques des syndromes associés au gène SCN4A, sur les implications physiologiques probables d’une telle mutation ainsi que sur les facteurs modulant le phénotype observé. Enfin, notre étude nous permet de souligner l’importance du dépistage familial systématique afin de prévenir les complications anesthésiques potentielles associées à ces conditions. / Congenital myotonic syndromes due to mutations of the voltage-gated sodium channel Nav1.4 differ from those due to mutations of the chloride channel CLC-1 as they tend to present atypical traits including painful myotonias and aggravation of symptoms with cold and potassium ingestion. Indeed, after completing the clinical and molecular characterization of a large cohort of patients affected with these rare conditions in the Saguenay Lac-St-Jean area, we were able to describe a new founder SCN4A mutation presenting with painful cold-induced myotonias and occasional dystrophic and paralytic episodes. Our study illustrates the wide phenotypic variability and the typical traits of SCN4A mutations. In addition, we were able to speculate on the probable physiological consequences of such mutations. Finally, we conclude by stressing the importance of familial screening in order to reduce the incidence of anesthetic complications associated with these conditions.

Les syndromes myotoniques congénitaux atypiques dus à des mutations du canal sodé voltage-dépendant Nav1.4 se distinguent des myotonies congénitales classiques (canal chlore ClC-1) par la présence de traits atypiques incluant des myotonies douloureuses aggravées au froid et à l’ingestion de potassium. La caractérisation clinique et moléculaire de plusieurs familles atteintes de ces conditions rares dans la région du Saguenay-Lac-St-Jean nous a permis de découvrir une nouvelle mutation SCN4A à effet fondateur causant un phénotype de myotonies douloureuses aggravées au froid, parfois accompagné de phénomènes dystrophiques ou paralytiques. L’ampleur de notre cohorte nous permet de commenter sur l’hétérogénité phénotypique observée, sur les traits caractéristiques des syndromes associés au gène SCN4A, sur les implications physiologiques probables d’une telle mutation ainsi que sur les facteurs modulant le phénotype observé. Enfin, notre étude nous permet de souligner l’importance du dépistage familial systématique afin de prévenir les complications anesthésiques potentielles associées à ces conditions. / Congenital myotonic syndromes due to mutations of the voltage-gated sodium channel Nav1.4 differ from those due to mutations of the chloride channel CLC-1 as they tend to present atypical traits including painful myotonias and aggravation of symptoms with cold and potassium ingestion. Indeed, after completing the clinical and molecular characterization of a large cohort of patients affected with these rare conditions in the Saguenay Lac-St-Jean area, we were able to describe a new founder SCN4A mutation presenting with painful cold-induced myotonias and occasional dystrophic and paralytic episodes. Our study illustrates the wide phenotypic variability and the typical traits of SCN4A mutations. In addition, we were able to speculate on the probable physiological consequences of such mutations. Finally, we conclude by stressing the importance of familial screening in order to reduce the incidence of anesthetic complications associated with these conditions.

No description available.

Clinical studies reported side effects of muscular spasms and muscle stiffness following the administration of clofibrate, a drug once used to treat hyperlipidaemia in patients. Experiments with clofibrate and its analogues in animal models showed it produced these myotonic symptoms in muscle by reducing the chloride conductance of the muscle membrane. The effects of 2-(4-chlorophenoxy)propionic acid, an analogue of clofibric acid, was assessed on the rat ClC-1 channel (rClC-1). Racemic 2-(4-chlorophenoxy)propionic acid shifted the voltage dependence of rClC-1 activation to more depolarising potentials, a mechanism accounting for myotonic symptoms previously reported. Experiments with resolved enantiomers revealed that the effects recorded were due exclusively to S-(–) 2-(4- chlorophenoxy)propionic acid. The R-(+) enantiomer was ineffective at the concentrations tested. Further experiments with the compound at differing Cl- concentrations in the extracellular solution suggested that S-(–) 2-(4-chlorophenoxy)propionic acid altered the gating of ClC-1 by decreasing the affinity of the binding site where Cl- normally acts to ‘gate’ the channel. Similarities in the effects reported for most dominant mutations in the CLCN1 gene that lead to myotonia congenita and 2-(4-chlorophenoxy)propionic acid prompted experiments that introduced these point mutations in the human ClC-1 (hClC-1) gene to compare their mode of action to that of the drug. These mutations, F307S and A313T, predominantly altered the slow, or common, gate of the channel. Conversely, the effect of 2-(4-chlorophenoxy)propionic acid was predominantly on the fast gating process of hClC-1. A macroscopically similar effect therefore, can be produced by two different modes of action. Results suggested that both drug and mutations exert their action by affecting the transition of the channel from its closed to open state subsequent to Cl- binding. Investigation of the interaction between rClC-1 gating and a further 25 compounds structurally related to clofibric acid identified a number of compounds effective at shifting the open probability of fast gating to depolarising potentials. Fewer were identified that influence slow gating. Some compounds affected both gating processes, however, none were identified which influenced slow gating alone. Ability to displace the voltage dependent activation of the fast gate appeared to depend largely on the lipophilicity of the molecules tested, indicating the importance of hydrophobic interactions between drug and channel protein. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1474724 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2009

No description available.

Abstract Functional defects in the muscle specific chloride channel ClC-1 result in reduced chloride conductance and electrical hyperexcitability, which in turn impairs muscle relaxation and leads to myotonia. The gene CLCN 1 codes for ClC-1 in humans, and mutations in CLCN 1 cause the disease known as myotonia congenita. Worldwide over 80 mutations in CLCN1 have been described, but only three were found in patients in Northern Finland. These included two missense mutations and a nonsense mutation. The behavior and localization of the normal and mutated ClC-1 mRNA and protein were analyzed in muscle cell cultures. In intact muscle the ClC-1 protein was seen in the sarcolemma, but after myofiber isolation the protein was located intracellularly. Sarcolemmal localization was restored when myofibers were electrically stimulated or treated with a protein kinase C inhibitor. When mutated ClC-1 proteins were examined in a myofiber cell culture system, retardation in the ER was observed with the two missense mutations. The nonsense mutation did not have an effect on the transport from the ER to the Golgi elements, but the mutated ClC-1 was degraded more rapidly than the wild type ClC-1, at least in myotubes. Both retardation and degradation of the mutated ClC-1 are likely to result in too few channels present at the plasma membrane of the muscle cell to maintain normal physiological function. A very strict quality control in muscle cells was observed. The behavior and survival of multinuclear skeletal muscle cells is dependent on innervation and muscle activity, and the balance between the phosphorylation and dephosphorylation pathways modulates the function of muscle chloride channels. / Tiivistelmä Lihasspesifisen kloridikanavan ClC-1:n toiminnalliset virheet johtavat alentuneeseen kloridin johtumiseen solukalvon läpi ja lihassolun ylieksitoitumiseen. Tämän seurauksena lihaksen rentoutuminen vaikeutuu ja havaitaan myotoniaa, lihasjäykkyyttä. Pohjoissuomalaisesta potilasmateriaalista tautiin johtavia geenimutaatioita löytyi kolme erilaista. Poikkeuksellista havainnoissa on erilaisten mutaatioiden vähyys, mikä on tyypillistä suomalaiselle tautiperinnölle. Yhteensä tämän kloridikanavan mutaatioita on julkaistu yli 80 erilaista. Tutkiessamme normaalin ja mutatoidun ClC-1 lRNA:n ja proteiinin käyttäytymistä ja sijaintia lihassoluviljelmissä. Havaitsimme eron lihasleikkeiden ja eristettyjen myofiibereiden välillä. Lihasleikkeissä ClC-1 paikantui solun pinnalle sarkolemmalle, mutta eristetyissä myofiibereissä lähinnä solun sisälle. Stimuloimalla eristettyjä myofiibereitä sähkövirralla tai käsittelemällä proteiini kinaasi C inhibiittorilla, saimme kloridikanava-proteiinin siirtymään takaisin solun pinnalle. Proteiinitasolla kuljetuksessa on havaittavissa eroja. Aminohappomuutokseen johtavat pistemutaatiot aiheuttivat proteiinin jäämisen endoplasmiseen kalvostoon, kun taas ennenaikaisen stop-kodonin johdosta lyhentynyt proteiini kuljetetaan eteenpäin Golgin laitteeseen. Myotuubeissa tämä lyhentynyt proteiini kuitenkin hajotettiin nopeammin kuin normaali kloridikanavaproteiini. Sekä kuljetuksen hidastuminen että nopeampi hajotus johtavat tilanteeseen, jossa lihassolun solukalvolla on liian vähän kloridikanavia ylläpitämään lihaksen normaalia fysiologista toimintaa. Monitumaisten lihassolujen laaduntarkkailu havaittiin vielä monitahoisemmaksi kuin yksitumaisilla. Monitumainen lihassolu on riippuvainen hermoärsytyksestä ja lihasaktiivisuudesta. Lisäksi fosforylaatioon liittyvä signalointi on tärkeää ClC-1 proteiinin oikealle paikantumiselle lihassolussa.